IRADIMED Toekomstige groei

Future criteriumcontroles 3/6

De verwachting is dat IRADIMED de winst en omzet met respectievelijk 15.5% en 13.9% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 14.6% per jaar.

Belangrijke informatie

15.5%

Groei van de winst

14.6%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.4%
Inkomstengroei	13.9%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	01 Nov 2024

Recente toekomstige groei-updates

Recent updates

IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

Aug 08

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Feb 23

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Feb 05

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

Oct 10

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Aug 23

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Aug 17

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

Jul 29

IRadimed: Reduce Equity Beta With Upside Capture

Jul 18

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Jul 13

At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?

Feb 05

Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital

Jan 12

Winst- en omzetgroeiprognoses

NasdaqGM:IRMD - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	99	27	N/A	N/A	1
12/31/2025	81	21	N/A	N/A	2
12/31/2024	73	19	N/A	N/A	2
9/30/2024	71	19	17	24	N/A
6/30/2024	69	19	13	16	N/A
3/31/2024	68	18	11	13	N/A
12/31/2023	66	17	5	13	N/A
9/30/2023	63	16	5	13	N/A
6/30/2023	60	15	7	15	N/A
3/31/2023	56	14	5	13	N/A
12/31/2022	53	13	8	10	N/A
9/30/2022	50	13	9	10	N/A
6/30/2022	48	12	9	10	N/A
3/31/2022	45	10	11	12	N/A
12/31/2021	42	9	11	11	N/A
9/30/2021	38	6	10	10	N/A
6/30/2021	35	5	8	8	N/A
3/31/2021	32	1	5	6	N/A
12/31/2020	32	1	5	6	N/A
9/30/2020	34	4	7	7	N/A
6/30/2020	36	5	8	9	N/A
3/31/2020	39	10	10	11	N/A
12/31/2019	39	10	10	10	N/A
9/30/2019	36	8	9	10	N/A
6/30/2019	34	8	7	7	N/A
3/31/2019	32	7	6	6	N/A
12/31/2018	30	6	7	7	N/A
9/30/2018	29	5	5	5	N/A
6/30/2018	27	3	N/A	6	N/A
3/31/2018	25	2	N/A	5	N/A
12/31/2017	23	0	N/A	3	N/A
9/30/2017	22	1	N/A	4	N/A
6/30/2017	24	3	N/A	6	N/A
3/31/2017	29	5	N/A	7	N/A
12/31/2016	32	7	N/A	9	N/A
9/30/2016	35	8	N/A	10	N/A
6/30/2016	35	9	N/A	9	N/A
3/31/2016	33	8	N/A	9	N/A
12/31/2015	31	8	N/A	8	N/A
9/30/2015	26	5	N/A	4	N/A
6/30/2015	22	4	N/A	3	N/A
3/31/2015	19	3	N/A	3	N/A
12/31/2014	15	2	N/A	3	N/A
9/30/2014	15	2	N/A	4	N/A
6/30/2014	14	2	N/A	3	N/A
3/31/2014	12	2	N/A	2	N/A
12/31/2013	11	2	N/A	1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei IRMD ( 15.5% per jaar) ligt boven de spaarquote ( 2.5% ).

Winst versus markt: De winst van IRMD ( 15.5% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.4% per jaar).

Hoge groeiwinsten: De winst van IRMD zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van IRMD ( 13.9% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van IRMD ( 13.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van IRMD naar verwachting over 3 jaar hoog zal zijn

IRADIMED Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Iradimed Corporation Revises Earnings Guidance for the Year 2024

IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024

Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Price target increased by 9.5% to US$57.50

IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023

Price target increased by 14% to US$52.50

Recent updates

Iradimed Corporation Revises Earnings Guidance for the Year 2024

IRADIMED CORPORATION to Report Q3, 2024 Results on Oct 31, 2024

IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

IRADIMED CORPORATION Declares A Regular Quarterly Cash Dividend, Payable on August 30, 2024

IRADIMED CORPORATION to Report Q2, 2024 Results on Aug 01, 2024

Independent Director recently sold US$84k worth of stock

Upcoming dividend of US$0.15 per share

IRADIMED CORPORATION Declares Regular Quarterly Cash Dividend, Payable on May 30, 2024

Now 25% overvalued

IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024

IRADIMED CORPORATION to Report Q1, 2024 Results on May 02, 2024

Now 21% overvalued

Now 21% overvalued after recent price rise

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024

Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

IRadimed Corporation to Report Q4, 2023 Results on Feb 08, 2024

Director notifies of intention to sell stock

IRadimed Corporation Approves Initiation of Regular Quarterly Dividend, Payable on January 12, 2024

Director notifies of intention to sell stock

Independent Director recently sold US$122k worth of stock

Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

IRadimed Corporation to Report Q3, 2023 Results on Nov 03, 2023

Founder notifies of intention to sell stock

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

Price target increased by 9.5% to US$57.50

IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

IRadimed Corporation to Report Q2, 2023 Results on Aug 03, 2023

Founder notifies of intention to sell stock

Independent Director recently sold US$128k worth of stock

Price target increased by 14% to US$52.50

IRadimed Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 16%

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Iradimed Corporation Approves Special Cash Dividend, Payable on February 21, 2023

IRadimed Corporation to Report Q4, 2022 Results on Feb 02, 2023

Investor sentiment improves as stock rises 16%

Price target increased to US$46.00

IRadimed Corporation Provides Earnings Guidance for the First Quarter of 2023 and Full Year 2023

Independent Director exercised options to buy US$87k worth of stock.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Iradimed Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

IRadimed Corporation to Report Q3, 2022 Results on Nov 03, 2022

IRadimed Corporation Provides Revenue Guidance for the Third Quarter Ended September 30, 2022

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

IRadimed Corporation Announces Board Changes

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Investor sentiment deteriorated over the past week

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Independent Director recently sold US$116k worth of stock

Insufficient new directors

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

IRadimed Corporation to Report Q2, 2022 Results on Jul 29, 2022

IRadimed: Reduce Equity Beta With Upside Capture

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Insufficient new directors

IRadimed Corporation Names John F. Glenn as Chief Financial Officer, Effective on or before June 20, 2022

Price target decreased to US$40.00

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$53.00